What is Collegium Pharmaceutical, Inc.'s azstarys — 2026?

Collegium Pharmaceutical, Inc. (COLL) reported azstarys — 2026 of $27.28M in Q2 2026.

What does azstarys — 2026 mean?

Represents the projected financial performance or specific asset-related metric for the Azstarys product line for the fiscal year 2026. This forward-looking data point assists in evaluating long-term revenue expectations and asset lifecycle management.

Collegium Pharmaceutical, Inc. (COLL) Azstarys — 2026

Screener

Other product segments

Jornay PM

$41.92M0.0%

Belbuca

$37.7M0.0%

Symproic

$3.64M0.0%

Similar metrics at other companies

FFord Credit — 2026

$2.09B+13.0%

LINE2023

$100M+7.5%

DT2023

$25.69M+38.1%

SF2023

$111.92M+2.4%

PRGO2023

$30.6M-7.8%

PIPR2023

$14.01M+1.6%

Other financials

Income statement

See full

Revenue$199.9M+6.3%

Gross profit$110.3M+1.8%

Operating income$3.7M-89.5%

Net income-$15.1M-226%

EPS (diluted)-$0.46-235%

Balance sheet

See full

Cash & equivalents$150.4M+8.8%

Total debt$5.0M-19.8%

Total equity$311.9M+34.3%

Total assets$2.1B+34.1%

Cash flow

See full

Operating cash flow$71.3M-1.5%

CapEx$496.0K+663%

Free cash flow$70.8M-2.1%

Valuation

See full

Market cap$955.82M-22.5%

Enterprise value$810.41M-26.8%

P/E20×-14.1×

P/S1.2×-0.6×

Profitability

See full

Gross margin60%+3.3pp

Operating margin19.5%+1.1pp

Net margin5.9%+0.8pp

FCF margin40.6%+10.8pp

Returns & leverage

See full

Return on equity17.6%+1.4pp

Debt / equity0×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 7:34 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001628280-26-053851

Years ended December 31,	Jornay PM	Azstarys	Belbuca	Symproic	Total
2026	$41,915	$27,283	$37,695	$3,643	$110,536
2027	83,829	54,567	—	7,285	145,681
2028	83,829	54,567	—	7,285	145,681
2029	83,829	54,567	—	7,285	145,681
2030	83,829	54,567	—	7,285	145,681
Thereafter	104,783	381,969	—	6,072	492,824
Remaining amortization expense	$482,014	$627,520	$37,695	$38,855	$1,186,084

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s azstarys — 2026?: Collegium Pharmaceutical, Inc. (COLL) reported azstarys — 2026 of $27.28M in Q2 2026.
What does azstarys — 2026 mean?: Represents the projected financial performance or specific asset-related metric for the Azstarys product line for the fiscal year 2026. This forward-looking data point assists in evaluating long-term revenue expectations and asset lifecycle management.